Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-26-047262
Filing Date
2026-04-23
Accepted
2026-04-23 07:45:36
Documents
20
Period of Report
2026-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A acrs-20260604xdef14a.htm   iXBRL DEF 14A 862104
2 GRAPHIC acrs-20260604xdef14a_a001.jpg GRAPHIC 3610
3 GRAPHIC acrs-20260604xdef14a_a011.jpg GRAPHIC 52554
4 GRAPHIC acrs-20260604xdef14a_a012.jpg GRAPHIC 53118
5 GRAPHIC acrs-20260604xdef14a_bg001.jpg GRAPHIC 123701
6 GRAPHIC acrs-20260604xdef14a_bg002.jpg GRAPHIC 93804
  Complete submission text file 0001104659-26-047262.txt   2713425

Data Files

Seq Description Document Type Size
7 EX-101.SCH acrs-20260604.xsd EX-101.SCH 3987
8 EX-101.DEF acrs-20260604_def.xml EX-101.DEF 3847
9 EX-101.LAB acrs-20260604_lab.xml EX-101.LAB 5711
10 EX-101.PRE acrs-20260604_pre.xml EX-101.PRE 4995
23 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20260604xdef14a_htm.xml XML 376328
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37581 | Film No.: 26885575
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)